Ben-Gurion University of the Negev Research and Development Authority

The National Institute for Biotechnology in the Negev Ltd.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Niv Papo

Yuval Zur

Noam Levaot

Lior Rosenfeld

Boris Yagen

Meir Blaler

Mutant M-CSF protein, comprising αβintegrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.

Compositions and methods for treatment of bone associated diseases

Mutant M-CSF protein, comprising &#x3b1;&#x3b2;integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.

The invention relates to pharmaceutical compositions and methods of preparation thereof suitable for the treatment of neurological, affective and psychotic disorders and for the treatment of pain and migraine comprising as an active ingredient an effective amount of 2-hydroxylpropyl valpormide and a pharmaceutically acceptable carrier or diluent. In a broader sense, the invention concerns 2-hydroxylpropyl valpromide (HP-VPD) of the formula:

Growing community of inventors

Raanana, Israel

Niv Papo